Literature DB >> 29463725

Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Lyndsay Avery1,2, Jessica Filderman3, Andrea L Szymczak-Workman1, Lawrence P Kane4.   

Abstract

Tim-3 is highly expressed on a subset of T cells during T cell exhaustion in settings of chronic viral infection and tumors. Using lymphocytic choriomeningitis virus (LCMV) Clone 13, a model for chronic infection, we found that Tim-3 was neither necessary nor sufficient for the development of T cell exhaustion. Nonetheless, expression of Tim-3 was sufficient to drive resistance to PD-L1 blockade therapy during chronic infection. Strikingly, expression of Tim-3 promoted the development of short-lived effector T cells, at the expense of memory precursor development, after acute LCMV infection. These effects were accompanied by increased Akt/mTOR signaling in T cells expressing endogenous or ectopic Tim-3. Conversely, Akt/mTOR signaling was reduced in effector T cells from Tim-3-deficient mice. Thus, Tim-3 is essential for optimal effector T cell responses, and may also contribute to exhaustion by restricting the development of long-lived memory T cells. Taken together, our results suggest that Tim-3 is actually more similar to costimulatory receptors that are up-regulated after T cell activation than to a dominant inhibitory protein like PD-1. These findings have significant implications for the development of anti-Tim-3 antibodies as therapeutic agents.

Entities:  

Keywords:  LCMV; T cell exhaustion; chronic infection; co-stimulation; mTOR

Mesh:

Substances:

Year:  2018        PMID: 29463725      PMCID: PMC5877951          DOI: 10.1073/pnas.1712107115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.

Authors:  Andrew Stamm; Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

2.  HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.

Authors:  Bahareh Vali; R Brad Jones; Ali Sakhdari; Prameet M Sheth; Kiera Clayton; Feng-Yun Yue; Gabor Gyenes; David Wong; Marina B Klein; Sahar Saeed; Erika Benko; Colin Kovacs; Rupert Kaul; Mario A Ostrowski
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

Review 3.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

4.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection.

Authors:  Afework Kassu; Roland A Marcus; Michelle B D'Souza; Elizabeth A Kelly-McKnight; Lucy Golden-Mason; Ramesh Akkina; Andrew P Fontenot; Cara C Wilson; Brent E Palmer
Journal:  J Immunol       Date:  2010-07-23       Impact factor: 5.422

6.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.

Authors:  Rajesh R Rao; Qingsheng Li; Kunle Odunsi; Protul A Shrikant
Journal:  Immunity       Date:  2010-01-07       Impact factor: 31.745

7.  TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells.

Authors:  Susumu Nakae; Motoyasu Iikura; Hajime Suto; Hisaya Akiba; Dale T Umetsu; Rosemarie H Dekruyff; Hirohisa Saito; Stephen J Galli
Journal:  Blood       Date:  2007-07-09       Impact factor: 22.113

8.  Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.

Authors:  Andrew N Macintyre; David Finlay; Gavin Preston; Linda V Sinclair; Caryll M Waugh; Peter Tamas; Carmen Feijoo; Klaus Okkenhaug; Doreen A Cantrell
Journal:  Immunity       Date:  2011-02-03       Impact factor: 31.745

Review 9.  Tim-3: an activation marker and activation limiter of innate immune cells.

Authors:  Gencheng Han; Guojiang Chen; Beifen Shen; Yan Li
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

10.  Endogenous antigen tunes the responsiveness of naive B cells but not T cells.

Authors:  Julie Zikherman; Ramya Parameswaran; Arthur Weiss
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

View more
  50 in total

1.  Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Authors:  Astero Klampatsa; Shaun M O'Brien; Jeffrey C Thompson; Abhishek S Rao; Jason E Stadanlick; Marina C Martinez; Maria Liousia; Edward Cantu; Keith Cengel; Edmund K Moon; Sunil Singhal; Evgeniy B Eruslanov; Steven M Albelda
Journal:  Oncoimmunology       Date:  2019-07-13       Impact factor: 8.110

2.  "Root"ing for successful T-ALL treatment.

Authors:  Sathish K R Padi; Andrew S Kraft
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113

Review 3.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

Review 4.  CEACAM1 structure and function in immunity and its therapeutic implications.

Authors:  Walter M Kim; Yu-Hwa Huang; Amit Gandhi; Richard S Blumberg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

5.  Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells.

Authors:  Miriam Victoria Martín-Manzo; Carlos Lara; Cruz Vargas-de-Leon; Julio Carrero; Gloria Queipo; Miguel Fonseca-Sanchez; Nancy R Mejia-Dominguez; David Kershenobich; Srinivas Mummidi; Alejandro Zentella-Dehesa; Joselin Hernandez
Journal:  Pathol Oncol Res       Date:  2019-02-13       Impact factor: 3.201

6.  Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.

Authors:  Jaitip Tipanee; Ermira Samara-Kuko; Thierry Gevaert; Marinee K Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2022-06-16       Impact factor: 12.910

7.  Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNγ-dependent mortality in STING gain-of-function mice.

Authors:  Kevin MingJie Gao; Mona Motwani; Thomas Tedder; Ann Marshak-Rothstein; Katherine A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-13       Impact factor: 12.779

8.  Exhausted PD-1+ TOX+ CD8+ T Cells Arise Only in Long-Term Experimental Trypanosoma cruzi Infection.

Authors:  Rosa Isela Gálvez; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

9.  Differential Expression of Immune Checkpoint Molecules on CD8+ T Cells Specific for Immunodominant and Subdominant Herpes Simplex Virus 1 Epitopes.

Authors:  Kate L Carroll; Lyndsay Avery; Benjamin R Treat; Lawrence P Kane; Paul R Kinchington; Robert L Hendricks; Anthony J St Leger
Journal:  J Virol       Date:  2020-01-06       Impact factor: 6.549

10.  TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma.

Authors:  Lihua Yu; Xiaoli Liu; Xinhui Wang; Fengna Yan; Peng Wang; Yuyong Jiang; Juan Du; Zhiyun Yang
Journal:  Oncoimmunology       Date:  2021-06-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.